Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAgly CD3 Phase II Extension in Recent-Onset Type 1 Diabetes
NCT00627146Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2000
- Primary completion
- Mar 2007
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of otelixizumab in type 1 diabetes mellitus (T1D), sponsored by AstraZeneca. Started Jun 2000; status: completed.
02
Drugs
otelixizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00627146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00627146.